Role of microRNAs in hematological malignancies research: A bibliometric analysis

MicroRNAs (miRNAs) are pivotal regulators of cancer biology, including hematological malignancies. Their roles include tumor suppression, oncogenic activities, modulation of immune responses, and treatment resistance. This study aimed to provide a quantitative analysis of research trends, thematic evolution, and key contributions to the field of miRNAs and hematological malignancies.

Using BIBLIO-Checklist and advanced visualization tools (VOSviewer and bibliometrix), data from key databases were analyzed for publication trends, author co-citations, thematic clusters, and emerging topics. Metrics such as the g-index, h-index, and m-index were used to assess author impact, while co-authorship networks and keyword co-occurrence patterns provided insights into collaboration and conceptual structure. This analysis was conducted from 2003 to 2024.

The analysis revealed a robust upward trajectory in the research output of miRNAs in hematological malignancies, with an annual growth rate of 27.41%. China, the USA, and Italy have emerged as leading contributors to the concentrated global interest. Core journals and prolific authors were identified, highlighting the influential works that shaped the field. Thematic evolution indicated an initial focus on foundational topics, such as acute myeloid leukemia and biomarkers, expanding to include chronic-lymphocytic leukemia, mesenchymal stem cells, and chemotherapy by 2017 to 2021. Recent research (2022-2024) emphasizes clinical applications, including drug resistance, immune infiltration, and targeted therapies. Co-citation analysis has identified key scholars, such as Calin and Anderson, leading to distinct thematic clusters. Investigation of the role of miRNAs in hematological malignancies has moved from initial identification to clinical translation, thus depicting increasing complexity and emphasis on personalized medicine.

Certain patterns, especially the contributions of key academic authors, spatial aspects of their distribution, and changes in sub-disciplinary focus, speak for an active developing discipline with considerable scope for novel approaches to treatment, as well as enhanced clinical management of patients with malignant diseases of the blood.